CSL Behring GmbH
26 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
12
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 4 to 18, 2027 · next Feb 4
- 1 fee due Mar 5, 2027The maintenance fee for Blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings (US 11,744,880) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
- 2 fees due Apr 8 to 15, 2027 · next Apr 8
- 1 fee due May 12, 2027The maintenance fee for Combination Therapy Using Immunoglobulin and C1-Inhibitor (US 10,471,142) comes due May 12, 2027. Unpaid by Nov 12, 2027, it lapses early.
- 1 fee due Jun 24, 2027The maintenance fee for Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies (US 10,513,560) comes due Jun 24, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 2 fees due Jul 2 to 26, 2027 · next Jul 2
- 1 fee due Sep 22, 2027The maintenance fee for Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life (US 9,290,561) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
Recent changes
- 2 terms have ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,887,797 | Immunoglobulin fractions In force · From the USPTO record | In force | From the USPTO record | |
| US 8,580,737 | Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates In force · From the USPTO record | In force | From the USPTO record | |
| US 8,715,652 | Immunoglobulin preparations having increased stability In force · From the USPTO record | In force | From the USPTO record | |
| US 8,877,711 | Octanoate-reduced human albumin In force · From the USPTO record | In force | From the USPTO record | |
| US 8,962,802 | Methods for Purification of ALPHA-1-Antitrypsin and Apolipoprotein A-1 In force · Medium confidence | In force | Medium confidence | |
| US 8,436,152 | Methods for purification of alpha-1-antitrypsin andapolipoprotein A-1 In force · From the USPTO record | In force | From the USPTO record | |
| US 8,394,768 | Synergistic therapeutic use of Prothrombin Complex Concentrates with FVIII concentrates In force · From the USPTO record | In force | From the USPTO record | |
| US 9,290,561 | Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life In force · From the USPTO record | In force | From the USPTO record | |
| US 9,095,564 | von Willebrand factor or factor VIII and von Willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes In force · From the USPTO record | In force | From the USPTO record | |
| US 10,137,165 | Factor H for the Treatment of Chronic Nephropathies and Production Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 60: 26 patents in force now held by others · 44 lapsed for an unpaid fee · 59 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 pending · 8 abandoned · 29 no status recorded